North Run Capital’s MaxCyte MXCT Stock Holding History

North Run Capital’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$2.47M	Sell	451,960 -105,000	-19%	-$644K	5.67%	6
2022 Q3	$3.62M	Sell	556,960 -82,000	-13%	-$457K	7.35%	6
2022 Q2	$3.02M	Buy	638,960 +158,060	+33%	+$779K	6.2%	7
2022 Q1	$3.36M	Buy	+480,900	New	+$3.28M	4.94%	8

Other funds holding MXCT

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

North Run Capital's MXCT Position: Q4 2022 in Review

North Run Capital reduced its MaxCyte (MXCT) stake by 19% in Q4 2022, selling an estimated $644K and leaving 451,960 shares worth $2.47M. The position accounts for 5.67% of the portfolio, ranked #6.

North Run Capital first reported a position in MXCT in Q1 2022 and has held it in 4 quarters since. The position peaked at $3.62M in Q3 2022. 104 funds tracked by Wall St. Rank hold MXCT as of Q4 2022.

North Run Capital held 451,960 shares of MaxCyte worth $2.47M as of Q4 2022.
North Run Capital sold 105,000 MaxCyte shares in Q4 2022, an estimated $644K.
MaxCyte made up 5.67% of North Run Capital's portfolio in Q4 2022, its #6 holding.
North Run Capital first reported a position in MaxCyte in Q1 2022 and has held it in 4 quarters since.
North Run Capital's MaxCyte position peaked at $3.62M in Q3 2022.
104 funds tracked by Wall St. Rank held MaxCyte as of Q4 2022.

Based on North Run Capital's 13F filing for Q4 2022, filed 14 Feb 2023.